Actively Recruiting

Phase 2
Age: 18Years - 64Years
All Genders
NCT07115329

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Led by Syndeio Biosciences, Inc · Updated on 2026-04-13

164

Participants Needed

32

Research Sites

125 weeks

Total Duration

On this page

Sponsors

S

Syndeio Biosciences, Inc

Lead Sponsor

W

Worldwide Clinical Trials

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel1)? What medical problems are observed in participants who take zelquistinel? Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

CONDITIONS

Official Title

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Who Can Participate

Age: 18Years - 64Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female subject
  • Aged 18 to 64 years, inclusive
  • Diagnosed with a first or recurrent episode of major depressive disorder (MDD) lasting between 3 weeks and 18 months, confirmed by DSM-5 and SCID-5-CT
  • Hamilton Depression Rating Scale-17 (HDRS-17) total score of 18 or higher at screening and baseline visits with no more than 25% change between visits
  • Hamilton Anxiety Rating Scale (HARS) total score of 15 or higher at screening and baseline visits
  • Insomnia Severity Index (ISI) total score of 10 or higher at screening and baseline visits
  • Female participants must be surgically sterile, postmenopausal for at least 2 years, or use acceptable birth control with a negative pregnancy test before starting treatment
  • Male participants must use medically acceptable contraception from randomization until the end of week 6 and inform female partners about birth control use
  • Able to understand study requirements, willing to comply with restrictions, and able to communicate with study staff
  • Provide written informed consent
  • Capable of completing patient-reported outcomes and reliably rated on assessment scales
  • Moderate or greater illness severity with a Clinical Global Impression - Severity (CGI-S) score of 4 or higher at screening and baseline visits
Not Eligible

You will not qualify if you...

  • Treatment-resistant MDD with inadequate response to two or more approved antidepressant medications during current episode
  • Current diagnosis of bipolar disorder, antisocial personality disorder, obsessive-compulsive disorder, borderline personality disorder, ADHD, PTSD, or panic attacks
  • Current or prior diagnosis of psychotic disorder or MDD with psychotic features
  • Score above 4 on the Clinician-Administered Dissociative States Scale (CADSS) at screening
  • Active seizure disorder
  • Traumatic brain injury with current symptoms
  • Treatment with esketamine, ketamine, psychedelic agents, or experimental depression treatments within past 12 months
  • Treatment with other experimental agents not for depression within past 3 months
  • Use of FDA-approved antidepressants or certain psychiatric medications within 14 days before baseline
  • Use of cannabis or cannabis-derived products within 14 days before baseline and positive THC test
  • Positive drug abuse test
  • Use of medical devices or digital therapies for psychiatric conditions within 90 days
  • History of electroconvulsive therapy or brain stimulation treatments within 5 years or failure of electroconvulsive therapy
  • Significant kidney or liver dysfunction
  • Resting pulse below 60 or above 100 bpm, or abnormal blood pressure or heart conduction measures
  • Alcohol abuse or positive alcohol screen
  • Substance abuse disorder within 12 months
  • Use of nicotine products within 14 days before randomization
  • Use of barbiturates unless stable dose for 3 months
  • Infection with HIV, COVID-19, active hepatitis B or C, syphilis, or other ongoing infections
  • Untreated or unstable hypothyroidism or diabetes
  • Pregnancy, nursing, or planning pregnancy
  • Working night shifts during study period
  • Recent malignancy except certain skin or cervical cancers
  • New or changed psychotherapy within 4 weeks before screening
  • Use of prohibited medications or herbal supplements that affect psychiatric assessments
  • Allergies or intolerance to study drug or related compounds
  • Prior participation in this or related studies
  • Body mass index over 40 kg/m2
  • Employment or family relation to study sponsors or investigators
  • Significant suicidal risk or history of suicidal attempts
  • Investigator or sponsor medical monitors judge subject inappropriate for study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 32 locations

1

NoesisPharma, LLC

Phoenix, Arizona, United States, 85028

Actively Recruiting

2

Del Sol Research Management

Tucson, Arizona, United States, 85710

Actively Recruiting

3

Catalina Research Institute, LLC

Montclair, California, United States, 91763

Actively Recruiting

4

Excell Research, Inc

Oceanside, California, United States, 92056

Actively Recruiting

5

Anderson Clinical Research

Redlands, California, United States, 92374

Actively Recruiting

6

Studyops Inc

San Francisco, California, United States, 94102

Actively Recruiting

7

Lumos Clinical Research Center

San Jose, California, United States, 95124

Actively Recruiting

8

Sunwise Clinical Research

Walnut Creek, California, United States, 94596

Not Yet Recruiting

9

Clinical Neuroscience Solutions, Inc

Jacksonville, Florida, United States, 32256

Not Yet Recruiting

10

Premier Clinical Research Institute Inc

Miami, Florida, United States, 33122

Not Yet Recruiting

11

Aqualane Clinical Research

Naples, Florida, United States, 34105

Actively Recruiting

12

EquiPath Health and Research Tampa Bay, LLC

Riverview, Florida, United States, 33578

Actively Recruiting

13

Neuroscience Research Institute

West Palm Beach, Florida, United States, 33407

Actively Recruiting

14

Denali Health Atlanta, LLC

Stone Mountain, Georgia, United States, 30038

Actively Recruiting

15

EmVenio Research

Chicago, Illinois, United States, 60622

Actively Recruiting

16

Tandem Clinical Research

Metairie, Louisiana, United States, 70006

Actively Recruiting

17

Sunstone Therapies

Rockville, Maryland, United States, 20850

Not Yet Recruiting

18

Continental Clinical Solutions

Towson, Maryland, United States, 21204

Actively Recruiting

19

Vitalix Clinical

Worcester, Massachusetts, United States, 01608

Actively Recruiting

20

Rochester Center for Behavioral Medicine

Rochester Hills, Michigan, United States, 48307

Not Yet Recruiting

21

Neurobehavioral Research, Inc

Cedarhurst, New York, United States, 11516

Not Yet Recruiting

22

IMA Clinical Research - NYC Midtown

New York, New York, United States, 10036

Not Yet Recruiting

23

IMA Clinical Research - NYC Uptown

New York, New York, United States, 10128

Actively Recruiting

24

UNC Health Rex

Raleigh, North Carolina, United States, 27607

Not Yet Recruiting

25

Insight Clinical Trials LLC

Independence, Ohio, United States, 44131

Not Yet Recruiting

26

Lehigh Center for Clinical Research

Allentown, Pennsylvania, United States, 18103

Not Yet Recruiting

27

Scranton Medical Institute, LLC

Moosic, Pennsylvania, United States, 18507

Terminated

28

Adams Clinical

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

29

Psychiatric Consultants, PC

Franklin, Tennessee, United States, 37067

Actively Recruiting

30

Elevate Synapsis, LLC

Atascocita, Texas, United States, 77346

Actively Recruiting

31

Synapsis Bio

Atascocita, Texas, United States, 77346

Not Yet Recruiting

32

Adams Clinical Dallas

DeSoto, Texas, United States, 75115

Not Yet Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here